AMBISOME
What it isPolyene binding fungal ergosterol and forming membrane pores; severe systemic mycoses.
Why this oneThe broadest antifungal spectrum available and a mainstay for cryptococcal meningitis and mucormycosis.
What limits it⚑ Liposomal and deoxycholate formulations are not interchangeable; product errors can be fatal. Nephrotoxicity and infusion reactions dominate.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Empirical therapy (presumed fungal infection in febrile neutropenia) | Adult/Pediatric | 3 mg/kg/day IV | ||
| Systemic fungal infections (Aspergillus, Candida, Cryptococcus) | Adult/Pediatric | 3-5 mg/kg/day IV | ||
| Cryptococcal meningitis in HIV-infected patients | Adult/Pediatric | 6 mg/kg/day IV | ||
| Visceral leishmaniasis (immunocompetent) | Adult/Pediatric | 3 mg/kg/day IV on days 1-5, 14, and 21 | ||
| Visceral leishmaniasis (immunocompromised) | Adult/Pediatric | 4 mg/kg/day IV on days 1-5, 10, 17, 24, 31, and 38 |
Renal Undefined
Hepatic Undefined
Pregnancy No adequate and well-controlled studies in pregnant women; systemic fungal infections have been successfully treated in pregnancy with amphotericin B deoxycholate.
Lactation Undefined
⚠ BOXED WARNING
Cost, est. cash$10–$500/month
Generic entry1987
Legacy pregnancy categoryB
Defining liabilitySevere nephrotoxicity, electrolyte wasting and infusion reactions require intensive monitoring.

Open Amphotericin B in the interactive console ↗

